Embracing collaboration

Learn about pioneering projects that have successfully secured the foundation’s support

Discover how the Foundation is supporting innovation in drug discovery and find out more about the groundbreaking projects that are benefiting from collaboration, GSK’s expertise, and the resources at the Tres Cantos Medicines Development Campus.

Related information

  • What we look for

    You could help transform the development of new medicines.

  • Support & funding

    Find out how your support could help shape the future of drug discovery.

2012

  • University Of Helsinki, Finland

    The benzimidazole derivatives synthesized at the University of Helsinki have shown activity against protozoan parasites.

    Start: December 2012 | Status: Active

  • Seattle BioMed, USA

    A Biochemist From The Seattle Biomedical Research Institute Joins The Tres Cantos Open Lab To Identify New Leads Against Tb.

    Start: November 2012 | Status: Active

  • Cornell Medical College, USA

    A Microbiologist From The Weill Cornell Medical College Joins The Tres Cantos Open Lab To Develop An Assay To Study Permeability Of Antituberculars.

    Start: September 2012 | Status: Active

  • University Of Liverpool, UK

    Researcher From The University Of Liverpool Joins The Tres Cantos Open Lab To Investigate A Series Of Antimalarial Compounds.

    Start: October 2012 | Status: Active

  • La Sapienza, University of Rome

    La Sapienza researcher joins the Tres Cantos Open Lab to work on hit-to-lead project on Tuberculosis.

    Start: September 2012 | Status: Active

  • NYU School of Medicine , USA

    NYU School of Medicine researcher joins the Tres Cantos Open Lab to investigate new treatments for Chagas disease.

    Start: April 2012 | Status: Active

  • Omnia Molecular, Spain

    Omnia Molecular, a Barcelona based Biotech Company, will apply its multi-parametric cell based assay to the identification of new anti-tubercular leads.

    Start: April 2012 | Status: Active

  • Northeastern University, USA

    This 12-Month project will be looking to identify kinase inhibitor compounds that can inhibit of african trypanosomes.

    Start: February 2012 | Status: Active

2011

  • CRESIB, Spain

    A two-year project to create a continuous lab-based supply of the P. vivax  malaria parasite in the blood stage.

    Start: May 2011 | Status: Active

  • CICbioGUNE, Spain

    An 18-month project to characterise the ubiquitylation profiles of cells infected by multiple drug resistant tuberculosis (TB) and the malaria parasite P.falciparum.

    Start: April 2011 | Status: Complete

  • Durham University, UK

    This 9-month project will be looking to identify compounds that can inhibit a new target in kinetoplastid protozoan parasites.

    Start: Q3 2011 | Status: Complete